UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

October 829, 2010 (Date of report)

CARACO PHARMACEUTICAL LABORATORIES, LTD.

(Exact name of registrant as specified in its charter)

Michigan		1-31773		38-2505723
(State or other jurisdiction of incorporation)		(Commission file number)		(I.R.S. employer identification no.)

1150 Elijah McCoy Drive, Detroit, Michigan 48202

(Address of principal executive offices)

(313) 871-8400

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 52.02. ~~Departure~~Results of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~Condition

~~(b) and (c)~~ On October 829, 2010, ~~the~~registrant ~~Board~~announced ~~appointed~~its ~~Gurpartap~~results ~~Singh Sachdeva to the position~~ of ~~Chief~~operations ~~Executive~~for ~~Officer effective November 1, 2010, following~~ the ~~resignation~~second ofquarter ~~Jitendra N. Doshi as interim Chief Executive Officer~~ and asfirst asix ~~Director,~~months ~~effective~~of ~~November~~Fiscal 12011, ~~2010. The~~as ~~disclosures~~set forth in the ~~attached~~ press release ~~with~~included ~~respect~~as toExhibit ~~the appointment and business background of Mr~~99.1 ~~Singh~~hereto and ~~the resignation of Mr. Doshi are~~ incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The disclosure in the attached press release with respect to the status of the Company’s remediation efforts is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibits.

Exhibit No. Description

99.1 Press ~~Release~~release of Caraco Pharmaceutical Laboratories, Ltd., dated October 829, 2010 announcing its results of operations for the second quarter and first six months of Fiscal 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARACO PHARMACEUTICAL LABORATORIES, LTD.

Date: October 8, 2010	By: /s/ Jitendra N. Doshi
Date: October 29, 2010	By: /s/ Jitendra N. Doshi
	Jitendra N. Doshi
	Chief Executive Officer

Exhibit Index

99.1 Press ~~Release~~release of Caraco Pharmaceutical Laboratories, Ltd., dated October 829, 2010 announcing its results of operations for the second quarter and first six months of Fiscal 2011.

Filing Compare · CARACO PHARMACEUTICAL LABORATORIES LTD